US BioPharma Player Makes Neulasta Biosimilars Claim

Multiple Pegfilgrastim Rivals Are Competing In The US Market

 
• By Dean Rudge
  
Cake
Over 70% of the pegfilgrastim market is still held by the two formulations of Neulasta • Source: Shutterstock

More from Biosimilars

More from Products